aid: hummingbird-bioscience
name: Hummingbird Bioscience
description: >-
  Hummingbird Bioscience is a clinical-stage precision biotherapeutics company headquartered at The
  Galen, Singapore Science Park, with US operations, discovering and developing antibody-based
  medicines — including next-generation antibody-drug conjugates (ADCs) — for hard-to-treat cancers
  and autoimmune disease. Its Rational Antibody Discovery (RAD) platform pairs computational target
  and epitope modelling with proprietary immunization strategies and Abvantage mice, and is combined
  with in-house linker-payload chemistry to engineer epitope-specific, high-affinity antibodies.
  Clinical programs include HMBD-001 (anti-HER3 monoclonal antibody) and HMBD-501 (HER3-targeted
  ADC, first patient dosed January 2026); HMBD-002 (anti-VISTA) was licensed to Percheron
  Therapeutics in 2025 and further antibodies were licensed to Immunome. The company sells drug
  programs and partnerships, not software: it publishes no developer program, API, SDK or
  machine-readable contract.
url: https://raw.githubusercontent.com/api-evangelist/hummingbird-bioscience/refs/heads/main/apis.yml
image: https://hummingbirdbioscience.com/wp-content/uploads/2022/12/social-share.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-22'
modified: '2026-08-22'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Antibody Therapeutics
- Oncology
- Precision Medicine
- Clinical Trials
- Singapore
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/hummingbird-bioscience-domain-security.yml
- type: Website
  url: https://hummingbirdbioscience.com/
- type: About
  url: https://hummingbirdbioscience.com/about-us/
- type: Science
  url: https://hummingbirdbioscience.com/science/
- type: Pipeline
  url: https://hummingbirdbioscience.com/pipeline/
- type: Publications
  url: https://hummingbirdbioscience.com/publications/
- type: News
  url: https://hummingbirdbioscience.com/news/
- type: Partnering
  url: https://hummingbirdbioscience.com/partnering/
- type: Contact
  url: https://hummingbirdbioscience.com/contact/
- type: Careers
  url: https://hummingbirdbioscience.com/careers/
- type: PrivacyPolicy
  url: https://hummingbirdbioscience.com/privacy-policy/
- type: GitHubOrganization
  url: https://github.com/hummingbirdbio
- type: LinkedIn
  url: https://www.linkedin.com/company/hummingbird-bioscience
- type: Twitter
  url: https://twitter.com/hummingbirdbio
- type: YouTube
  url: https://www.youtube.com/channel/UCmPba8fq01BA7ArZPo51HGg
- type: SecondaryMarketListing
  url: https://forgeglobal.com/hummingbird-bioscience_stock/
- type: Packages
  url: packages/hummingbird-bioscience-packages.yml
- type: LLMsTxt
  url: llms/hummingbird-bioscience-llms.txt
x-enrichment:
  date: '2026-08-22'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Hummingbird Bioscience is a clinical-stage biotherapeutics developer whose products are
    antibodies and ADCs licensed to pharma partners — its WordPress corporate site has no
    developer, docs or API section anywhere in its navigation, its own GitHub organization
    (github.com/hummingbirdbio) has zero public repositories, and no api./docs./developer.
    subdomain resolves.
  evidence:
    - url: https://hummingbirdbioscience.com/
      status: 202
    - url: https://web.archive.org/web/20260107084440id_/https://hummingbirdbioscience.com/
      status: 200
    - url: https://api.github.com/orgs/hummingbirdbio/repos
      status: 200
    - url: https://hummingbirdbioscience.com/.well-known/agent-card.json
      status: 202
    - url: https://pypi.org/pypi/hummingbird-bioscience/json
      status: 404
  checked: '2026-08-22'